Eliem pursues acquisition of New Jersey biotech after halting programs

14d ago, source:

With the Tenet deal, announced Thursday, Eliem said it is now focusing on Tenet's candidate TNT119, which is aimed at a ...

Eliem Therapeutics Shifts From Neurology With New Found Focus On Autoimmune Diseases With Tenet Medicines Deal

15d ago, source:

Eliem Therapeutics Inc (NASDAQ:ELYM) has agreed to acquire Tenet Medicines Inc., a development-stage private biotechnology ...

Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement

15d ago, source:

NDAQ:ELYM) Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement ...

Eliem Therapeutics to buy Tenet, announces $120 million private placement

on MSN ago, source:

Eliem Therapeutics ( NASDAQ: ELYM) on Thursday said, it would acquire Tenet Medicines, as the combined company plans to focus on clinical development of lead product candidate, TNT119, in upcoming ...

ELYM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Eliem Therapeutics, Inc. Is Fair to Shareholders

15d ago, source: The Bakersfield Californian

Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Eliem Therapeutics, Inc. (NASDAQ: ELYM) and Tenet Medicines, Inc. is fair to Eliem shareholders.

Seamless Therapeutics Announces New CEO and Board Chairman to Support US Expansion of Programmable Recombinase Gene Editing Technology Platform

3d ago, source:

Seamless Therapeutics today announced the appointments of Albert Seymour, Ph.D., as its new President and Chief Executive ...

Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

15d ago, source:

Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial results.

Tryp Therapeutics Set To Finalize Merger With Exopharm, Announces Trading Halt Ahead Of ASX Listing

on MSN ago, source:

Tryp Therapeutics finalizes merger with Exopharm, prepares for ASX listing with strategic shareholder benefits. Explore ...

Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease Study

on MSN ago, source:

Cerevel Therapeutics Holdings Inc. (NASDAQ:CERE) released topline results from its pivotal Phase 3 TEMPO-3 trial for ...

Severity of Resistant Depression Predicts Ketamine vs ECT Response

2d ago, source: Medscape

The severity of TRD appeared to predict response to IV ketamine vs ECT. However, experts said more research is needed before ...